New products: Rozlytrek (entrectinib) 100 mg and 200mg hard capsules

Entrectinib is licensed for use as monotherapy for the treatment of certain adult and paediatric patients ≥12 years of age with solid tumours expressing a neurotrophic tyrosine receptor kinase gene fusion, and for the treatment of adults with ROS1-positive, advanced NSCLC.


electronic Medicines compendium